Discovery of HSD-621 as a potential agent for the treatment of type 2 diabetes

ACS Medicinal Chemistry Letters

Volumn 4, Issue 1, 2013, Pages 118-123

  Wan, Zhao Kui ^a   Chenail, Eva ^a   Li, Huan Qiu ^a   Ipek, Manus ^a   Xiang, Jason ^a   Suri, Vipin ^a   Hahm, Seung ^a   Bard, Joel ^a   Svenson, Kristine ^a   Xu, Xin ^a   Tian, Xianbin ^a   Wang, Mengmeng ^a   Li, Xiangping ^a   Johnson, Christian E ^a   Qadri, Ariful ^a   Panza, Darrell ^a   Perreault, Mylene ^a   Mansour, Tarek S ^a   Tobin, James F ^a   Saiah, Eddine ^a  

^a PFIZER INC   (United States)

Author keywords

11 hydroxysteroid dehydrogenase type I (HSD1); diet induced obesity; piperazine sufonamides; type II diabetes

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 3,3,3 TRIFLUORO 2 [5 [[4 [4 FLUORO2 (TRIFLUOROMETHYL)PHENYL] 2 METHYLPIPERAZIN 1 YL]SULFONYL]THIOPHEN 2 YL] 2 HYDROXYPROPANAMIDE; ANTIDIABETIC AGENT; GLUCOSE; HSD 621; INSULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; LIPID DIET; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

CANIS FAMILIARIS; MUS; RATTUS; TRIFLUORO;

EID: 84872355231     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300352x     Document Type: Article

References (35)

1. Ozoles, J. Lumenal Orientation and Post-translational Modifications of the Liver Microsomal 11β-Hydroxysteroid Dehydrogenase J. Biol. Chem. 1995, 270, 2305-2312
2. Odermatt, A.; Arnold, P.; Stauffer, A.; Frey, B. M.; Frey, F. J. J. Biol. Chem. 1999, 274, 28762-28770
3. Seckl, J. R.; Walker, B. R. 11β-Hydroxysteroid dehydrogenase type 1-a tissue-specific amplifier of glucocorticoid action Endocrinology 2001, 142, 1371-1376
4. Stulnig, T. M.; Waldhausl, W. 11β-Hydroxysteroid dehydrogenase type 1 in obesity and type 2 diabetes Diabetologia 2004, 47, 1-11
5. For a few selected reviews, see Walker, B. R.; Seckl, J. R. 11β-Hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease Expert Opin. Ther. Targets 2003, 7, 771-783
6. Tomlinson, J. W.; Walker, E. A.; Bujalska, I. J.; Draper, N.; Lavery, G. G.; Cooper, M. S.; Hewison, M.; Stewart, P. M. 11β-Hydroxysteroid dehydrogenase type 1: A tissue-specific regulator of glucocorticoid response Endocr. Rev. 2004, 25, 831-866
7. Hollis, G.; Huber, R. 11β-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus Diabetes, Obes. Metab. 2010, 13, 1-6
8. Hosfield, D. J.; Wu, Y.; Skene, R. J.; Hilgers, M.; Jennings, A.; Snell, G. P.; Aertgeerts, K. Conformational flexibility in crystal structures of human 11 β -hydroxysteroid dehydrogenase type I provide insights into glucocorticoid interconversion and enzyme regulation J. Biol. Chem. 2005, 280, 4639-4648
9. Draper, N.; Walker, E. A.; Bujalska, I. J.; Tomlinson, J. W.; Chalder, S. M.; Arlt, W.; Lavery, G. G.; Bedendo, O.; Ray, D. W.; Laing, I.; Malunowicz, E.; White, P. C.; Hewison, M.; Mason, P. J.; Connell, J. M.; Shackleton, C. H.; Stewart, P. M. Nat. Genet. 2003, 34, 434-439
10. Albiston, A. L.; Obeyesekere, V., R.; Smith, R. E.; Krozowski, Z. S. Cloning and tissue distribution of human 11β-hydroxysteroid dehydrogenase type 2 enzyme Mol. Cell Endocrinol. 1994, 105, R11-R17
11. Masuzaki, H.; Peterson, J.; Shinyama, H.; Morton, N. M.; Mullins, J. J.; Seckl, J. R.; Flier, J. S. A transgenic model of visceral obesity and the metabolic syndrome Science 2001, 294, 2166-2170
12. Masuzaki, H.; Yamamoto, H.; Kenyon, C. J.; Elmquist, J. K.; Morton, N. M.; Paterson, M. M.; Shinyama, H.; Sharp, M. G.; Fleming, S.; Mullins, J. J.; Seckl, J. R.; Flier, J. S. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice J. Clin. Invest. 2003, 112, 83-88
13. Kotelevtsev, Y.; Holmes, M. C.; Burchell, A.; Houston, P. M.; Schmoll, D.; Jamieson, P.; Best, R.; Vrown, R.; Edwards, C. R.; Seckl, J. R.; Mullins, J. J. 11 Beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 14924-14929
14. Morton, N. M.; Paterson, M.; Masuzaki, H.; Holmes, M.; Staels, B.; Fievet, C.; Walker, B.; Flier, J. S.; Mullins, J. J.; Seckl, J. R. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type-1 deficient mice Diabetes 2004, 53, 931-938
15. Stimson, R. H.; Andrew, R.; McAvoy, N. C.; Tripathi, D.; Hayes, P. C.; Walker, B. R. Increased whole-body and sustained liver cortisol regeneration by 11β-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition Diabetes 2011, 60, 720-725
16. Xiang, J.; Wan, Z.-K.; Li, H.-Q.; Ipek, M.; Binnun, E.; Nunez, J.; Chen, L.; McKew, J. C.; Mansour, T. S.; Xu, X.; Suri, V.; Tam, M.; Xing, Y.; Li, X.; Hahm, S.; Tobin, J.; Saiah, E. Piperazine sulfonamides as potent, selective, and orally available 11β-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model J. Med. Chem. 2008, 51, 4068-4071
17. Wan, Z.-K.; Chenail, E.; Xiang, J.; Li, H.-Q.; Ipek, M.; Bard, J.; Svenson, K.; Mansour, T. S.; Xu, X.; Tian, X.; Suri, V.; Hahm, S.; Xing, Y.; Johnson, C. E.; Li, X.; Qadri, A.; Panza, D.; Perreault, M.; Tobin, J.; Saiah, E. Efficacious 11β-hydroxysteroid dehydrogenase type 1 inhibitors in the diet-induced obesity mouse model J. Med. Chem. 2009, 52, 5449-5461
18. Su, X.; Pradaux-Caggiano, F.; Thomas, M. P.; Szeto, M.W. Y.; Halem, H. A.; Culler, M. D.; Vicker, N.; Potter, B. V. L Discovery of adamantyl ethanone derivatives as potent 11β-hydroxysteroid dehydrogenase Type 1 (11β-HSD1) Inhibitors ChemMedChem 2010, 5, 1026-1044
19. Veniant, M. M.; Hale, C.; Hungate, R. W.; Gahm, K.; Emery, M. G.; Jona, J.; Joseph, S.; Adams, J.; Hague, A.; Moniz, G.; Zhang, J.; Bartberger, M. D.; Li, V.; Syed, R.; Jordan, S.; Komorowski, R.; Chen, M. M.; Cupples, R.; Kim, K. W.; St. Jean, D. J., Jr.; Johansson, L.; Henriksson, M. A.; Williams, M.; Vallgarda, J.; Fotsch, C.; Wang, M. Discovery of a potent, orally active 11β-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: Identification of (S)-2-((1 S,2 S,4 R)-bicyclo[2.2.1]heptan-2-ylamino)-5- isopropyl-5-methylthiazol-4(5H)-one (AMG 221) J. Med. Chem. 2010, 53, 4481-4487
20. Torres-Piedra, M.; Ortiz-Andrade, R.; Villalobos-Molina, R.; Singh, N.; Medina-Franco, J. L.; Webster, S. P.; Binnie, M.; Navarrete-Vazquez, G.; Estrada-Soto, S. A comparative study of flavonoid analogues on streptozotocin-nicotinamide induced diabetic rats: Quercetin as a potential antidiabetic agent acting via 11β-Hydroxysteroid dehydrogenase type 1 inhibition Eur. J. Med. Chem. 2010, 45, 2606-2612
21. Rollinger, J. M; Kratschmar, D. V; Schuster, D.; Pfisterer, P. H; Gumy, C.; Aubry, E. M; Brandstotter, S.; Stuppner, H.; Wolber, G.; Odermatt, A. 11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational approaches Bioorg. Med. Chem. 2010, 18, 1507-15
22. Venier, O.; Pascal, C.; Braun, A.; Namane, C.; Mougenot, P.; Crespin, O.; Pacquet, F.; Mougenot, C.; Monseau, C.; Onofri, B.; Dadji-Faihun, R.; Leger, C.; Ben-Hassine, M.; Van-Pham, T.; Ragot, J.-L.; Philippo, C.; Guessregen, S.; Engel, C.; Farjot, G.; Noah, L.; Maniani, K.; Nicolai, E. Pyrrolidine-pyrazole ureas as potent and selective inhibitors of 11β-hydroxysteroid- dehydrogenase type 1 Bioorg. Med. Chem. Lett. 2011, 21, 2244-2251
23. Sun, W.; Maletic, M.; Mundt, S. S.; Shah, K.; Zokian, H.; Lyons, K.; Waddell, S. T.; Balkovec, J. Substituted phenyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1 Bioorg. Med. Chem. Lett. 2011, 21, 2141-2145
24. Li, A.; Yuan, C. C.; Chow, D.; Chen, M.; Emery, M. G.; Hale, C.; Zhang, X.; Subramanian, R.; St. Jean, D., Jr.; Komorowski, R.; Veniant, M.; Wang, M.; Fostsch, C. Synthesis and Evaluation of the Metabolites of AMG 221, a Clinical Candidate for the Treatment of Type 2 Diabetes ACS Med. Chem. Lett. 2011, 2, 824-827
25. Ye, X.-Y.; Chen, S. Y.; Nayeem, A.; Golla, R.; Seethala, R.; Wang, M.; Harper, T.; Sleczka, B. G.; Li, Y.-X.; He, B.; Kirby, M.; Gordon, D. A.; Robl, J. A. Design, synthesis, and SAR studies of novel polycyclic acids as potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) Bioorg. Med. Chem. Lett. 2011, 21, 6669-6704
26. Scott, J. S.; Bowker, S. S.; deSchoolmeester, J.; Gerhardt, S.; Hargreaves, D.; Kilgour, E.; Lloyd, A.; Mayers, R. M.; McCoull, W.; Newcombe, N. J.; Ogg, D.; Packer, M. J.; Rees, A.; Revill, J.; Schofield, P.; Selmi, N.; Swales, J. G.; Whittamore, P. R. O. J. Med. Chem. 2012, 55, 5951-5964
27. Barf, T.; Vallgarda, J.; Emond, R.; Haggstrom, C.; Kurz, G.; Nygren, A.; Larwood, V.; Mosialou, E.; Axelsson, K.; Olsson, R.; Engblom, L.; Edling, N.; Ronquist-Nii, Y.; Ohman, B.; Alberts, P.; Abrahmsen, L. J. Med. Chem. 2002, 45, 3813-3815
28. Alberts, P.; Engblom, L.; Edling, N.; Forsgren, M.; Klingstrom, G.; Larsson, C.; Ronquist-Nii, Y.; Ohman, B.; Abrahmsen, L. Diabetologia 2002, 45, 1528
29. Alberts, P.; Nilsson, C.; Selen, G.; Engblom, L. O.; Edling, N. H.; Norling, S.; Klingstrom, G.; Larsson, C.; Forsgren, M.; Ashkzari, M.; Nilsson, C. E.; Fiedler, M.; Bergqvist, E.; Ohman, B.; Bjorkstrand, E.; Abrahmsen, L. B. Endocrinology 2003, 144, 4755
30. Hermanowski-Vosatka, A.; Balkovec, J. M.; Cheng, K.; Chen, H. Y.; Hernandez, G. C.; Koo, G. C.; LeGrand, C. B.; Li, Z.; Metzger, M. M.; Mundt, S. S.; Noonan, H.; Nunes, C. N.; Olson, S. H.; Pikounis, B.; Ren, N.; Robertson, N.; Schaeffer, M. M.; Shah, K.; Springer, M. S.; Strack, A. M.; Strowski, M.; Wu, K.; Wu, T.; Xiao, J.; Zhang, B. B.; Wright, S. D.; Thieringer, R. J. Exp. Med. 2005, 202, 517
31. Bhat, B. G.; Hosea, N.; Fanjul, A.; Herrera, J.; Chapman, J.; Thalacker, F.; Stewart, P. M.; Rejto, P. A. Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4′-cyano-biphenyl- 4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11β-hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys J. Pharmacol. Exp. Ther. 2008, 324, 299-305
32. Rosenstock, J.; Banarer, S.; Fonseca, V. A.; Inzucchi, S. E.; Sun, W.; Yao, W.; Hollis, G.; Flores, R.; Levy, R.; Williams, W. V.; Seckl, J. R.; Huber, R. The 11β-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy Diabetes Care 2010, 33, 1516-1522
33. Paterson, J. M.; Morton, N. M.; Fievet, C.; Kenyon, C. J.; Holmes, M. C.; Staels, B.; Seckl, J. R.; Mullins, J. J. Metabolic syndrome without obesity: Hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 7088-7093
34. Wan, Z.-K.; Chenail, E.; Li, H.-Q.; Kendall, C.; Wang, Y.; Gingras, S.; Xiang, J.; Massefski, W.; Mansour, T. S.; Saiah, E. Synthesis of potent and efficacious 11β-hydroxysteriod dehydrogenase type I inhibitor HSD-016 J. Org. Chem. 2011, 76, 7048-7055
35. Aahni-Arya, B.; Flynn, M. J.; Bergeron, L.; Salyan, M. E. K.; Pedicord, D. L.; Golla, R.; Ma, Z.; Wang, H.; Seethala, R.; Wu, S. C.; Li, J. J.; Nayeem, A.; Gates, C.; Hamann, L. G.; Gordon, D. A.; Blat, Y. Cofactor-specific modulation of 11β-hydroxysteroid dehydrogenase 1 inhibitor potency Biochim. Biophys. Acta 2007, 1774, 1184-1191